bullish
Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones
309 Views21 Mar 2018 20:17
WuXi Biologics (Cayman) Inc. (2269 HK) plans to raise around US$600m through a mix of primary (85%) and secondary (15%) offering. This will be the...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Wuxi Biologics Placement - Past Deals Have Done Well but Progressive Returns Are Getting Lower20 Mar 2019
- WuXi Biologics – The Foxconn or Qualcomm of Global CDMO?14 Jan 2019
- Wuxi Biologics Placement - Probably Not a Surprise to Sell Again when Lock-Up Expires19 Jun 2018
- Wuxi Biologics Placement - Selldown Right when Lockup Expires Suggests Eagerness to Offload13 Dec 2017
- Biosimilar Battlefield: U.S. Humira Pushed to 202304 Oct 2017
x